It has constant tyrosine kinase activity leading to uncontrolled cell proliferation.[1–3] Tyrosine kinase inhibitors (TKIs) blocking the BCR-ABL1 oncokinase activity have revolutionized the treatment and prognosis of CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.